Key Developments In The Pharmaceutical Industry 2025
Last week, several significant events in the pharmaceutical industry have captured attention, signaling important shifts in investment strategies, acquisitions,... Read more.
Pfizer’s Adcetris Receives FDA Approval For Treating Large B-Cell Lymphoma
Pfizer’s Adcetris (brentuximab vedotin) has secured a new FDA approval to treat patients with large B-cell lymphoma (LBCL), marking another milestone for the... Read more.
Merck KGaA In Advanced Talks To Acquire Springworks Therapeutics Amid Fda Decision On Key Drug
Merck KGaA, the German biopharma giant, is in advanced discussions to acquire SpringWorks Therapeutics, a Connecticut-based company specializing in cancer and rare... Read more.
CRISPR Gene-Editing Offers Hope For Muscular Dystrophy Treatment
Researchers at the Experimental and Clinical Research Center (ECRC) in Berlin have made a significant breakthrough in the development of a gene-editing therapy for... Read more.
Three-Drug Cocktail Boosts Car-T Cell Therapy’s Potential In Cancer Treatment
Preclinical research from the University of North Carolina Lineberger Comprehensive Cancer Center has revealed a promising cocktail of three different drugs that... Read more.
Takeda Launches Innovation Centre, Aiming To Attract AI-Driven Talent
Takeda, a leading Japanese pharmaceutical company, has announced the launch of its new Innovation Centre, with a strong focus on leveraging artificial intelligence... Read more.
Biocon Appeals To Indian Government For Tax Exemption On Cancer And Rare-Disease Drugs In Budget
Biocon, a leading biopharmaceutical company, has urged the Indian government to exempt cancer and rare-disease drugs from taxes in the upcoming Union Budget. This... Read more.
Trends in Preventive Healthcare – Reviving the Age-Old Practices
“Prevention is better than care” as they say, this age-old phrase has never been more relevant. With the aging population, rising incidence of chronic diseases,... Read more.
U.S. Prescription Drug Prices to Rise in 2025, Driven by High-Cost Treatments
The cost of prescription drugs in the U.S. is projected to continue rising in 2025 and beyond, driven by a steady stream of high-cost treatments. A recent survey... Read more.
Biogen Challenges Eli Lilly in the Alzheimer’s Treatment Race with Leqembi vs. Kisunla
As the Alzheimer’s drug market intensifies, Biogen is preparing for a fierce competition against Eli Lilly’s newly approved Alzheimer’s treatment, Kisunla.... Read more.
Avel eCare Acquires Amwell Psychiatric Care to Expand Behavioral Health Services Nationwide
Avel eCare has acquired Amwell Psychiatric Care, a division of Amwell, to expand its behavioral health services across the United States. This acquisition will allow... Read more.
Top 10 Pharmaceutical Breakthroughs Set to Become Blockbusters in 2025
As we look ahead to 2025, the pharmaceutical industry is set for some major shifts, with several top-selling drugs dominating the market. While AbbVie’s Humira... Read more.
Oropouche Fever – The emerging health threat with promising market opportunities 2025
What is oropouche fever? Oropouche fever caused by the Oropouche virus (OROV) is predominant in Central America, South America, and the Caribbean region. The virus... Read more.